Nec-1s is extensively used in preclinical studies, and several other RIPK1 inhibitors (e.g., DNL474, DNL758) are currently in clinical trials for neurodegenerative diseases suggesting the translational potential of these inhibitors for age-related neuroinflammation and cognitive decline [88]. Here, RIPK1 is linked to neurodegenerative disease.